Payment overview · 2025
General Payments
$5,677.51
114 reported records · 38 companies
Healthcare provider profile · identity verified
Fernando Cristobal Diaz, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · MCALLEN, TX · NPI 1902333545
Verified facts
What the public records show
CMS Open Payments records show Fernando Cristobal Diaz, MD received $5,677.51 in general payments during 2025 across 114 reported records.
Boston Scientific Corporation accounted for 43.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 66 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $2,487.69 | 43.8% | 8 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $302.01 | 5.3% | 13 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $248.21 | 4.4% | 9 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $224.04 | 4.0% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $198.20 | 3.5% | 4 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $161.62 | 2.9% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $140.21 | 2.5% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $139.44 | 2.5% | 7 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $135.33 | 2.4% | 2 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $134.57 | 2.4% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$129.59 | 2.3% | 1 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $124.40 | 2.2% | 2 | 2025 |
| SEAGEN INC. | Unresolved — no canonical attribution shown | $99.95 | 1.8% | 1 | 2025 |
| Galvanize Therapeutics, Inc | Unresolved — no canonical attribution shown | $91.06 | 1.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $85.87 | 1.5% | 6 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $83.67 | 1.5% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $82.53 | 1.4% | 3 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $76.69 | 1.4% | 3 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $70.69 | 1.2% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $66.53 | 1.2% | 3 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $65.12 | 1.1% | 2 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $64.02 | 1.1% | 1 | 2025 |
| Caris MPI, Inc. | Unresolved — no canonical attribution shown | $52.42 | 0.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $38.71 | 0.7% | 2 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $37.12 | 0.7% | 2 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $36.98 | 0.7% | 2 | 2025 |
| Ferring Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.76 | 0.7% | 2 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $35.47 | 0.6% | 2 | 2025 |
| Genmab U.S., Inc. | Unresolved — no canonical attribution shown | $29.18 | 0.5% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $24.99 | 0.4% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $24.23 | 0.4% | 1 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $23.68 | 0.4% | 1 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $23.24 | 0.4% | 1 | 2025 |
| Syndax Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.70 | 0.4% | 1 | 2025 |
| Deciphera Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.52 | 0.4% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.12 | 0.3% | 1 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.00 | 0.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.95 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,209.57 | 105 |
| Travel and Lodging | $907.89 | 2 |
| Education | $560.05 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TheraSphere Y90 Glass Microspheres 10 GBq Normalized: therasphere y90 glass microspheres 10 gbq |
Device | Boston Scientific Corporation | $2,329.01 | 6 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $296.61 | 12 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $248.21 | 9 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $224.04 | 7 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $183.53 | 3 | 2025 |
Source payment records
|
|||||
| TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial) Normalized: therasphere y90 glass microspheres 7 0 gbq us commercial |
Device | Boston Scientific Corporation | $158.68 | 2 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $140.21 | 3 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $134.57 | 3 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $134.17 | 4 | 2025 |
Source payment records
|
|||||
| OSTEOCOOL RF ABLATION SYSTEM Normalized: osteocool rf ablation system |
Device | Medtronic, Inc. | $129.59 | 1 | 2025 |
Source payment records
|
|||||
| COSELA Normalized: cosela |
Drug | Pharmacosmos Therapeutics Inc. | $125.01 | 1 | 2025 |
Source payment records
|
|||||
| ALIYA SYSTEM Normalized: aliya system |
Device | Galvanize Therapeutics, Inc | $91.06 | 1 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Drug | Janssen Biotech, Inc. | $79.96 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $66.53 | 3 | 2025 |
Source payment records
|
|||||
| ZEPZELCA Normalized: zepzelca |
Drug | JAZZ PHARMACEUTICALS INC. | $65.12 | 2 | 2025 |
Source payment records
|
|||||
| CODMAN CERTAS Normalized: codman certas |
Device | Integra LifeSciences Corporation | $64.02 | 1 | 2025 |
Source payment records
|
|||||
| CODMAN HAKIM Normalized: codman hakim |
Device | Integra LifeSciences Corporation | $64.02 | 1 | 2025 |
Source payment records
|
|||||
| CUSA CLARITY Normalized: cusa clarity |
Device | Integra LifeSciences Corporation | $64.02 | 1 | 2025 |
Source payment records
|
|||||
| DuraSeal Exact Spinal Sealant System Normalized: duraseal exact spinal sealant system |
Device | Integra LifeSciences Corporation | $64.02 | 1 | 2025 |
Source payment records
|
|||||
| OPDUALAG Normalized: opdualag |
Drug | E.R. Squibb & Sons, L.L.C. | $63.56 | 3 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $52.61 | 3 | 2025 |
Source payment records
|
|||||
| MI CANCER SEEK Normalized: mi cancer seek |
Device | Caris MPI, Inc. | $52.42 | 2 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | ARRAY BIOPHARMA INC, PFIZER INC. | $51.70 | 4 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $48.13 | 2 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $47.78 | 2 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $45.04 | 2 | 2025 |
Source payment records
|
|||||
| Tecentriq Normalized: tecentriq |
Biological | Genentech USA, Inc. | $39.34 | 2 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $38.71 | 2 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $38.70 | 2 | 2025 |
Source payment records
|
|||||
| CABLIVI Normalized: cablivi |
Biological | GENZYME CORPORATION | $37.34 | 1 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $37.12 | 2 | 2025 |
Source payment records
|
|||||
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $36.98 | 2 | 2025 |
Source payment records
|
|||||
| ADSTILADRIN Normalized: adstiladrin |
Biological | Ferring Pharmaceuticals Inc. | $36.76 | 2 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $35.47 | 2 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $35.47 | 2 | 2025 |
Source payment records
|
|||||
| Itovebi Normalized: itovebi |
Biological | Genentech USA, Inc. | $31.35 | 1 | 2025 |
Source payment records
|
|||||
| Epkinly Normalized: epkinly |
Drug | Genmab U.S., Inc. | $29.18 | 1 | 2025 |
Source payment records
|
|||||
| POMALYST Normalized: pomalyst |
Drug | Celgene Corporation | $28.91 | 1 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $28.02 | 3 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc. | $27.45 | 2 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc. | $27.45 | 2 | 2025 |
Source payment records
|
|||||
| FRUZAQLA Normalized: fruzaqla |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $24.99 | 1 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $24.41 | 1 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $24.23 | 1 | 2025 |
Source payment records
|
|||||
| INLYTA Normalized: inlyta |
Drug | PFIZER INC. | $23.95 | 1 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $23.95 | 1 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $23.68 | 1 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $23.68 | 1 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $23.24 | 1 | 2025 |
Source payment records
|
|||||
| QINLOCK Normalized: qinlock |
Drug | Deciphera Pharmaceuticals Inc. | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| TGCT Normalized: tgct |
Drug | Deciphera Pharmaceuticals Inc. | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| RETEVMO Normalized: retevmo |
Drug | Lilly USA, LLC | $21.12 | 1 | 2025 |
Source payment records
|
|||||
| Stivarga Normalized: stivarga |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.97 | 1 | 2025 |
Source payment records
|
|||||
| Vitrakvi Normalized: vitrakvi |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.97 | 1 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $20.11 | 1 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| TIVDAK Normalized: tivdak |
Biological | PFIZER INC. | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| BLENREP Normalized: blenrep |
Biological | GlaxoSmithKline, LLC. | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC. | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | PFIZER INC. | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| EMRELIS Normalized: emrelis |
Drug | ABBVIE INC. | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $10.32 | 1 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $5.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Mirtazapine | Mirtazapine | 33 | 14 |
| Gabapentin | Gabapentin | 23 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 23 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 19 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 17 | suppressed |
| Losartan Potassium | Losartan Potassium | 16 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 12 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,677.51 · 114 records | Boston Scientific Corporation | ADSTILADRIN, ALIYA SYSTEM, BLENREP, BRAFTOVI, CABLIVI, CABOMETYX, CARVYKTI, CODMAN CERTAS, CODMAN HAKIM, COSELA, CUSA CLARITY, DARZALEX, DATROWAY, DuraSeal Exact Spinal Sealant System, EMRELIS, Enhertu, Epkinly, FOTIVDA, FRUZAQLA, Fabhalta, IBRANCE, INLYTA, INQOVI, Itovebi, JAYPIRCA, KEYTRUDA, KISQALI, LONSURF, Lenvima, MEKTOVI, MI CANCER SEEK, MONJUVI, MONOFERRIC, Nubeqa, OPDIVO, OPDUALAG, ORGOVYX, OSTEOCOOL RF ABLATION SYSTEM, Onivyde, Orserdu, PADCEV, POMALYST, PYRUKYND, QINLOCK, REBLOZYL, RETEVMO, RYBREVANT, RYTELO, SARCLISA, SCEMBLIX, Stivarga, TALVEY, TALZENNA, TGCT, TIVDAK, TUKYSA, Tecentriq, TheraSphere Y90 Glass Microspheres 10 GBq, TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial), Trodelvy, VENCLEXTA, VERZENIO, Vitrakvi, XPOVIO, XTANDI, ZEPZELCA | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error